Edoxaban (DU-176b) is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Ki values of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban can be used in preventing thromboembolic disease research.
Edoxaban (1, 1 and 5 minutes respectively) prolongs PT,TT and APTT of human plasma in a concentration-dependent manner.
Edoxaban inhibits thrombin-induced platelet aggregation, with an IC50 of 2.90 μM.
Medlife has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay
Cell Line:
Human, rat, cynomolgus monkey and rabbit plasma; Human platelet
Concentration:
Incubation Time:
1 and 5 minutes
Result:
Antithrombin.
体内研究(In Vivo)
Edoxaban (0.5, 2.5 and 12.5 mg/kg; p.o.; once) significantly and dose-dependently reduces the thrombus formation and prolongs PT.
Medlife has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:
Male Slc: Wistar rats (210-240 g); Male New Zealand White rabbits(2.5-3.5 kg) (Both are venous stasis thrombosis model).